This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT06354660 |
|---|---|
| Status | Completed |
| Phase | Phase 3 |
| Sponsor | Eli Lilly and Company |
| Enrollment | 537 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Diabetes Type 2 |
| Interventions | Retatrutide; Placebo |
| Start | Apr 10, 2024 |
| Primary completion | Jan 22, 2026 |
| Study completion | Feb 20, 2026 |
| Results posted | Not yet |
| Registry last updated | Mar 5, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control. The study will last about 11 months and may include up to 11 visits.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Change from Baseline in Hemoglobin A1c (HbA1c) (%) | Baseline, Week 40 |
13 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
